Ushbu ishga iqtibos qilgan ishlar

3 ta ish

Ish: Bispecific T‐cell engagers for cancer immunotherapy

1. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

   Manh-Cuong Vo, Van-Dinh-Huan Tran, Van‐Tan Nguyen +5

   MaqolaOAOchiq kirishCAR-T cell therapy researchJournal of Hematology & Oncology20251 iqtibos

   ABIABI:AkademIndex/2025.article.000083

2. Exploring cellular immunotherapy platforms in multiple myeloma

   Manh-Cuong Vo, Sunghoon Jung, Van‐Tan Nguyen +11

   MaqolaOAOchiq kirishCAR-T cell therapy researchHeliyon20241 iqtibos

   ABIABI:AkademIndex/2026.other.102962

3. Bispecific and multispecific immune engagers for redirecting innate and adaptive immunity against hematologic cancers

   Mustafa T. Ardah, Waleed K. Abdulsahib, Ihsan Khudhair Jasim +6

   MaqolaOAOchiq kirishMonoclonal and Polyclonal Antibodies ResearchDiscover Oncology20260 iqtibos

   ABIABI:AkademIndex/2026.article.005315